Female desire pill awaiting FDA approval

290 views · Published 19 August 2015 · 2:06 · Indexed 23 October 2026

Channel: LOCAL 12 · 2015 · News & Politics

Watch on YouTube

CINCINNATI (Liz Bonis) -- No word yet from the Food and Drug Administration on the approval of a new medication for women to boost desire.      It was expected Tuesday, August 18, and it could make history. The drug would be the first prescription medication available for younger women, those in their 20's, 30's and 40's that are pre-menopausal, to boost sexual desire. It is called Flibanserin and was expected to be marketed under the name Addy-1. The little pink pill would be a daily medication which studies show can help improve a condition called hypo-sexual activity desire disorder or HSDD. Dr. Lisa Larkin of UC Women's Health in West Chester recently testified on Capitol Hill and recommended its approval. She said it worked to alter brain chemicals in those who have HSDD and returns their desire to normal. People would take it much like they would an antidepressant. Local 12 News also talked to women who said after more than 20 medications on the market targeted toward mens sexual health it was about time there was one to address the women's health need. Renee Jackson said, Desire really opens the door for feeling connected, having pleasure with each other and if you can have that closeness, then you are going to have the highest level of intimacy that you could ever possibly want." Dr. Larkin said, This is a brand new drug in a class by itself. We really have nothing to date, there's no currently approved FDA medications for womens sexual health so this is really like making history." Since the FDA usually takes the committee's recommendations, approval was expected. Local 12 News will of course continue to follow the story and report it as soon as a decision is announced.      It was turned down for approval a number of times, due to side effects including concerns about a drop in blood pressure. But those for it said it has also been difficult to convince an FDA panel that HSDD actually was a true medical concern. Follow Liz Bonis on Twitter @lbonis1, and LIKE her on Facebook. Follow us on Twitter @Local12 and LIKE us on Facebook for updates!

More from this channel